Company Information

  

Address: 4960 PEACHTREE INDUSTRIAL BOULEVARD
SUITE 240 
City: NORCROSS 
State: GA 
Zip Code: 30071 
Telephone: 678-620-3186 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

We are a clinical stage biopharmaceutical company engaged in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Our drug candidates are based on our method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. We use naturally occurring, readily-available plant products as starting material in manufacturing processes to create proprietary complex carbohydrates with specific molecular weights and other pharmaceutical properties. These complex carbohydrate molecules are appropriately formulated into acceptable pharmaceutical formulations. Using these unique carbohydrate-based candidate compounds that largely bind and inhibit galectin proteins, particularly galectin-3, we are undertaking the focused pursuit of therapies for indications where galectins have a demonstrated role in the pathogenesis of a given disease.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-0.61NAN/E
03/2017-0.67NAN/E
12/2016-0.76NAN/E
09/2016-0.83NAN/E
06/2016-0.89NAN/E
03/2016-0.90NAN/E
12/2015-0.88NAN/E
09/2015-0.87NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.13Total Liab/Total Assets0.24
Net Inc/Total Assets-1.36Total Liab/Inv Cap0.31
Net Inc/Inv Cap-1.78Total Liab/Comm Equity0.02
Pretax Inc/Net SalesNAInterest Coverage RatioNA
Net Inc/Net SalesNACurr Debt/EquityNA
Cash Flow/Net SalesNALTD/EquityNA
SG&A/NetSalesNATotal Debt/EquityNA
Asset Utilization   Liquidity  
Net Receivables TurnoverNAQuick Ratio4.18
Inventory TurnoverNACurrent Ratio4.18
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work CapNAInv/Curr AssetsNA
Net Sales/PP&ENA  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) NA NA NA NA
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 1.07 1.17 1.17 1.25
Operating Income -4.51 -4.95 -4.60 -4.54
Interest Exp NA NA NA NA
Pretax Income -4.51 -4.94 -4.59 -4.53
Other Income 0.01 0.01 0.01 0.01
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -4.51 -4.94 -4.59 -4.53

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 9.13 13.64 15.36 16.06
Receivables - Total NA NA NA NA
Inventories - Total NA NA NA NA
Total Current Assets 9.33 14.00 15.79 16.11
Net Property, Plant & Equipment NA NA 0.00 NA
Total Assets 9.33 14.00 15.80 16.12
Liabilities        
Accounts Payable 3.51 4.36 3.78 4.09
Debt in Current Liabilities NA NA NA NA
Total Current Liabilities 3.51 4.36 3.78 4.09
Long-Term Debt NA NA NA NA
Total Liabilities 3.51 4.36 3.78 4.09
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 7.24 7.24 7.24 6.62
Common Stock 0.04 0.04 0.03 0.03
Retained Earnings -173.72 -168.91 -163.70 -158.52
Treasury Stock NA NA NA NA
Total Stockholders' Equity 4.09 7.91 10.29 10.31
Total Liabilities and Stockholders' Equity 7.61 12.27 14.07 14.39

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -5.00 -3.86 -4.87 -3.44
Net Cash Provided by Investing Activities NA NA 0.00 0.00
Net Cash Provided by Financing Activities 0.49 2.15 4.17 1.50

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20120.00-9.68-0.72
12/20130.00-12.09-1.30
12/20140.00-15.79-0.78
12/20150.00-20.03-0.88
12/20160.00-21.44-0.76
Growth RatesNaN----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17553,91811.18




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.